Orphan Designation Requests To Get Slower Reviews
This article was originally published in The Pink Sheet Daily
FDA can't keep pace with requests, placing more pressure on sponsors to ensure submissions are complete.
You may also be interested in...
US FDA's Orphan Drug Designation Reviews Often Don't Include Regulatory Histories, GAO Says
Lack of information may mean FDA cannot conduct a thorough review, but HHS argues that products usually are very early in development and therefore don't have a regulatory history to document.
US FDA Appoints Another Orphan Products Development Office Head Amid Growth Expectations
Janet Maynard will become acting Office of Orphan Products Development director at the end of October, the fourth head of the office in the last 10 months; staff is expected to grow and may begin to provide development advice.
US FDA's Acting Orphan Products Development Director Has Gene Therapy Background
Ilan Irony will take over as acting director of the Office of Orphan Products Development later this month.